Provided by Tiger Trade Technology Pte. Ltd.

Eli Lilly

1,156.44
-18.1700-1.55%
Volume:1.07M
Turnover:1.24B
Market Cap:1.09T
PE:38.82
High:1,171.45
Open:1,168.04
Low:1,147.00
Close:1,174.61
52wk High:1,292.65
52wk Low:712.05
Shares:945.38M
Float Shares:939.00M
Volume Ratio:0.67
T/O Rate:0.11%
Dividend:6.69
Dividend Rate:0.58%
EPS(TTM):29.79
EPS(LYR):22.95
ROE:102.29%
ROA:20.36%
PB:32.27
PE(LYR):50.39

Loading ...

Stick with Value Stocks Until Everyone Starts Talking About Them - and as of Now They're Still Under the Radar, This Wall Street Firm Says

Dow Jones
·
Aug 25

Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Eli Lilly & Co (LLY)

TIPRANKS
·
Aug 25

Eli Lilly Stock (LLY) in Focus as Hedge Fund Titan Ken Griffin Quadruples Position

TIPRANKS
·
Aug 25

Sector Update: Healthcare

MT Newswires Live
·
Aug 25

Eli Lilly’s New Obesity Drug LY3549492 Moves Forward With Completed Phase 1 Trial

TIPRANKS
·
Aug 25

Eli Lilly (LLY) On Foundayo Launch And Higher Outlook Faces A Rich Valuation

Simply Wall St.
·
Aug 24

Roche, Eli Lilly's Alzheimer's Blood Test Gets FDA Clearance

Reuters
·
Aug 24

Barclays Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

TIPRANKS
·
Aug 24

Eli Lilly: Working with Nice on Assessment of Foundayo for Potential Use on Nhs in England

THOMSON REUTERS
·
Aug 24

Eli Lilly Launches Oral Weight-Loss Pill Foundayo in UK

Reuters
·
Aug 24

Eli Lilly: Foundayo NOW Available in UK to be Prescribed for Eligible Adults Via Private Prescription

THOMSON REUTERS
·
Aug 24

Eli Lilly: in UK, Foundayo is Priced Lower than Mounjaro; Likely to be in Order of £100 to £120

THOMSON REUTERS
·
Aug 24

Eli Lilly Targets Ramadan Diabetes Market With New Orforglipron Trial

TIPRANKS
·
Aug 22

Eli Lilly’s Dulaglutide Study Sheds Light on Fasting Risks and Diabetes Care

TIPRANKS
·
Aug 22

Pharma Stocks Have Rallied. 2 Stocks to Avoid-and 2 to Buy.

Dow Jones
·
Aug 21

Eli Lilly Advances Early-Stage Eloralintide Trial: What Investors Should Watch

TIPRANKS
·
Aug 21

Eli Lilly’s Lebrikizumab Trial Completion Signals New Growth Path in Atopic Dermatitis

TIPRANKS
·
Aug 21

Eli Lilly Revenue Jumps 48% as Mounjaro and Zepbound Sales Reach $14.9B

TradingKey
·
Aug 20

Pharma Sector Doubles Down on AI Amid Hopes of Slashing Costs, Timelines

Reuters
·
Aug 20

7 Growth Stocks Holding up in a Tough Market

Dow Jones
·
Aug 20